New drug combo battles tough kidney cancer after first treatment fails
NCT ID NCT07165418
Summary
This study compares two different drug combinations for people with advanced kidney cancer whose first treatment has stopped working. 116 participants will be randomly assigned to receive either vorolanib tablets plus everolimus or the standard drug sunitinib. The goal is to see which combination better controls the cancer's growth and is safer for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Cancer Hospital
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.